Survival after oxaliplatin therapy of irinotecan-pretreated advanced colorectal cancer patients

Hepato-Gastroenterology

Volumn 52, Issue 66, 2005, Pages 1707-1714

  Melichar, Bohuslav ^a   Kohlová, Tereza ^a   Vesely, Pavel ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Colorectal carcinoma; Irinotecan; Oxaliplatin

Indexed keywords

FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; RALTITREXED;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; DEATH; FEMALE; HAZARD; HEMOGLOBIN DETERMINATION; HUMAN; LIVER CIRCULATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPHIL; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SURVIVAL;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 28544442971     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C: Cancer mortality in Europe, 1990-1994, and an overview of trends from 1955 to 1994. Eur J Cancer 1999; 35:1477-1516.
2. Lee CYTM: Carcinoma of the colon and rectum: Distribution of metastatic sites, risk factors and autopsy studies. GI Cancer 1998; 2:255-266.
3. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Brit Med J 1993; 306:752-755.
4. Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Expectancy or primary chemotherapy in patients with advanced colorectal cancer: a randomized trial. J Clin Oncol 1992; 10:904-911.
5. Piedbois P, Zelek L, Cherqui D: Chemotherapy for non-operable colorectal liver metastases. Hepatogastroenterology 2001; 48:711-714.
6. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset JL, Levi F: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10:663-669.
7. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
8. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343:905-914.
9. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
10. Andre T, Bensmaine MA, Louvet C, Francois E, Lucas V, Desseigne F, Beerblock K, Bouche O, Carola E, Merrouche Y, Morvan F, Dupont-Andre G, de Gramont A: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999; 17:3560-3568.
11. Maindrault-Goebel F, Louvet C, Andre T, Carola E, Lotz JP, Molitor JL, Garcia ML, Gilles-Amar V, Izrael V, Krulik M, de Gramont A: Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer 1999; 35:1338-1342.
12. Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, Carola E, Mabro M, Artru P, Gilles V, Lotz JP, Izrael V, Krulik M: High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX7). Eur J Cancer 2001; 37:1000-1005.
13. Goldberg RM, Morton RF, Sargent DJ, Fuchs C, Ramanathan RK, Williamson SK, Findlay BP: N9741: oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an intergroup study. Proc ASCO 2003; 22:252.
14. Kouroussis C, Souglakos J, Mavroudis D, Papadouris S, Kakolyris S, Agelaki S, Kalbakis K, Panopoulos C, Vardakis N, Sarra E, Georgoulias V: Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC). Am J Clin Oncol 2002; 25:627-631.
15. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 2003; 21:2059-2069.
16. Janinis J, Papakostas P, Samelis G, Skarlos D, Papagianopoulos P, Fountzilas G: Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: A Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. Ann Oncol 2000; 11:163-167.
17. Luppi G, Zanelli F, Di Stasi A, Bertolini F, Pifferi M: FOLFOX2 regimen in heavily pretreated patients with advanced colorectal cancer. Tumori 2002; 88:270-272.
18. Moehler M, Hoffmann T, Hildner K, Siebler J, Galle PR, Heike M: Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens. Z Gastroenterol 2002; 40:957-964.
19. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981; 47:207-214.
20. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 2001; 19:3801-3807.
21. Melichar B, Dvorak J, Jandik P, Touskova M, Malirova E, Mergancova J, Voboril Z: Regional administration of irinotecan in combination with 5-fluorouracil and leucovorin in patients with colorectal cancer liver metastases - a pilot experience. Hepatogastroenterology 2001; 48:1721-1726.
22. Solichova D, Melichar B, Blaha V, Klejna M, Vavrova J, Palicka V, Zadak Z: Biochemical profile and survival in nonagenarians. Clin Biochem 2001; 34:563-569.
23. Cunningham D, Pyrhonen S, James RD, Punt CJA, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-1418.
24. Bensmaine MA, Marty M, de Gramont A, Brienza S, Levi F, Ducreux M, Francois E, Gamelin E, Bleiberg H, Cvitkovic E: Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. Brit J Cancer 2001; 85:509-517.
25. Brienza S, Bensmaine MA, Soulie P, Louvet C, Gamelin E, Francois E, Ducreux M, Marty M, Andre T, de Braud F, Bleiberg H, Segal V, Itzhaki M, Cvitkovic E: Oxaliplatin added to 5-fluorouracil-based therapy (5-FU ± FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): Results from the European compassionate-use program. Ann Oncol 1999; 10:1311-1316.
26. Weiss G, Kronberger P, Conrad F, Bodner E, Wachter H, Reibnegger G: Neopterin and prognosis in patients with adenocarcinoma of the colon. Cancer Res 1993; 53:260-265.
27. Reibnegger G, Fuchs D, Fuith LC, Hausen A, Werner ER, Werner-Felmayer G, Wachter H: Neopterin as a marker for activated cell-mediated immunity: Application in malignant disease. Cancer Detect Prev 1991; 15:483-490.
28. Mathur P, Allen-Mersh TG: Hepatic arterial chemotherapy for colorectal liver metastases. Hepatogastroenterology 2001; 48:317-319.
29. Lygidakis NJ, Sgourakis G, Dedemadi G, Safioleas MC, Nestoridis J: Regional chemoimmunotherapy for non-resectable metastatic disease of colorectal origin. A prospective randomized study. Hepatogastroenterology 2001; 48:1085-1087.
30. Melichar B, Voboril Z, German J, Melicharova K, Mergancova J, Voboril R, Jandik P: Survival of patients with colorectal cancer liver metastases treated by regional chemotherapy. Hepatogastroenterology 2006. (In press)
31. Ducreux M, Ychou M, Laplanche A, Gamelin E, Husseini F: Intra-arterial hepatic chemotherapy with oxaliplatin combine to intravenous treatment with 5FU + folinic acid in hepatic metastases of colorectal cancer. Eur J Cancer 2001; 37:S19.
32. Kern W, Berckert B, Lang N, Stemmler J, Beykirch M, Stein J, Goecke E, Waggerhauser T, Braess J, Schalhorn A, Hiddemann W: Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Ann Oncol 2001; 12:599-603.
33. Louhimo J, Carpelan-Holmstrom M, Alfthan H, Stenman UH, Jarvinen HJ, Haglund C: Serum HCGbeta, CA72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer 2002; 101:545-548.
34. Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R: Multivariate analysis of the prognostic value of CEA and CA19-9 serum levels in colorectal cancer. Anticancer Res 2000; 20:5195-5198.
35. Figueras J, Valls C, Rafecas A, Fabregat J, Ramos E, Jaurrieta E: Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Brit J Surg 2001; 88:980-985.
36. Zink S, Kayser G, Gabius HJ, Kayser K: Survival, disease-free interval, and associated tumor features in patients with colon/rectal carcinomas and their resected intra-pulmonary metastases. Eur J Cardiothorac Surg 2001; 19:90-913.
37. Kemeny N, Braun DW: Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. Am J Med 1983; 74:786-794.
38. Hannisdal E, Thorsen G: Regression analyses of prognostic factors in colorectal cancer. J Surg Oncol 1988; 37:109-112.
39. Graf W, Glimelius B, Pahlman L, Bergstrom R: Determinants of prognosis in advanced colorectal cancer. Eur J Cancer 1991; 27:1119-1123.
40. Freyer G, Rougier P, Bugat R, Droz JP, Marty M, Bleiberg H, Mignard D, Award L, Herait P, Culine S, Trillet-Lenoir V: Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients give irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. Brit J Cancer 2000; 83:431-437.
41. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, Itzhaki M, Metzger G, N Daw D, Vignoud J, Abad A, Francois E, Gamelin E, Marty M, Sastre J, Seitz JF, Ychou M: Two consecutive phase II studie of oxaliplatin (L-OHP) for treatment of patients with advaced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7:95-98.
42. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Muller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD: Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 20:1759-1766.
43. Scheithauer W, Kornek GV, Schuell B, Ulrich-Pur H, Penz M, Raderer M, Lang F, Schneeweiss B, Lenauer A, Depisch D: Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. Ann Oncol 2001; 12:709-714.
44. Scheithauer W, Kornek GV, Raderer M, Valencak J, Weinlander G, Hejna M, Haider K, Kwasny W, Depisch D: Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimide/leucovorin-pretreated colorectal cancer. J Clin Oncol 1999; 17:902-906.
45. Chau I, Webb A, Cunningham D, Hill M, Waters JS, Norman A, Massey A: Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. Br J Cancer 2001; 85:1258-1264.
46. Kern W, Berckert B, Lang N, Waggerhauser T, Braess J, Schalhorn A, Hiddemann W: Hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer: Role of carcinoembryonic antigen in assessment of response. Anticancer Res 2000; 20:4973-4976.
47. Gamelin E, Le Bouil A, Boisdron-Celle M, Turcant A, Delva R, Cailleux A, Krikorian A, Brienza S, Cvitkovic E, Robert J, Larra F, Allain P: Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin Cancer Res 1997; 3:891-899.
48. Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, Cohen D, Hopwood P, Johnston C, Stephens RJ: Comparison of survival, palliation, and quality of life with three chemotherapy regiments in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002; 359:1553-1563.
49. Tournigand C, Louvet C, Quinaux E, Andre T, Lledo G, Flesch M, Ganem G, Landi B, Colin P, Denet C, Mery-Mignard D, Risse M, Buyse M, de Gramont A: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. Proc ASCO 2001; 20:124a.
50. Comella P, De Vita F, De Lucia L, Casaretti R, Avallone A, Orditura M, Rivellini F, Palmeri S, Catalano G, Comella G: Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: A dose finding study in advanced previously treated colorectal carcinoma. Ann Oncol 2000; 11:461-468.
51. Recchia F, Rea S, Nuzzo A, Lalli A, Di Lullo L, De Filipis S, Saggio G, Di Blasio A, Massa E, Mantovani G: Multicenter phase II study of fractionated bimonthly oxaliplatin with leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer, pre-treated with chemotherapy. Oncol Rep 2003; 10:65-69.